The first of its kind in the world, our registries hold 15 years of data on ophthalmic treatment outcomes for neovascular (wet) age-related macular degeneration (wet AMD).
Our system tracks and analyses "real world" patient treatment outcomes for some of the leading causes of visual impairment, including neovascular age-related macular degeneration (“wet” AMD), atrophy, choroidal neovascularisation, diabetic retinopathy, retinal vein occlusion, glaucoma, keratoconus, dry eye, uveitis, inherited retinal diseases, uveal melanoma, and retinopathy of prematurity. The Registries are an international project, and has collected data from Europe, Asia, Africa and North America.
The Save Sight Registries consist of seven registries:
Our registries are immediately relevant to clinicians, researchers, public health providers and policy makers seeking to fight ocular blindness and improve patient outcomes in Australia and internationally.
The Registries' standardised dataset is compliant with international measurement tools for health outcomes (ICHOM) for our neovascular age-related macular degeneration module and enables current and emerging therapies to be evaluated for clinical efficacy, cost-effectiveness and safety.